Long-Term Incidence of Hematological Evolution in Three French Prospective Studies of Hydroxyurea and Pipobroman in Polycythemia Vera and Essential Thrombocythemia

ABSTRACT

Despite recent discoveries made in myeloproliferative disorders other than chronic myelogenous leukemia, which it is hoped will result in earlier diagnosis, and better evaluation and management of patients, hematological evolution to myelofibrosis, acute leukemia, and myelodysplastic syndromes (AL/MDS) remain major causes of long-term mortality in polycythemia vera (PV) and essential thrombocythemia (ET) patients. Evaluation of long-term leukemogenic risk of currently available drugs, therefore, is crucial. We report updated results of three French prospective trials of hydroxyurea and pipobroman in PV and ET patients with a median follow-up longer than 10 years. The results show that the incidence of AL/MDS is higher than previously reported with no evidence of a plateau (with ~40% of AL/MDS cases occurring after the 12th year of follow-up). Although hydroxyurea currently remains the first choice in the treatment of high-risk PV and ET patients, the use of nonleukemogenic drugs, such as interferon α (IFN-α) or anagrelide, should be assessed more widely in randomized trials using accurate diagnostic criteria and taking into account the presence of the JAK2 mutation, given that they may have an impact on disease evolution.

Polycythemia vera - essential thrombocythemia - leukemogenic risk - hydroxyurea - anagrelide - interferon - pipobroman

REFERENCES

• 1 Michiels J J, Berneman Z N, Schroyens W, Van Vliet H H. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.  Platelets. 2004;  15 67-84
• 2 Barbui T, Barosi G, Grossi A et al.. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.  Haematologica. 2004;  89 215-232
• 3 McMullin M F, Bareford D, Campbell P et al.. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis.  Br J Haematol. 2005;  130 174-195
• 4 Berk P D, Goldberg J D, Donovan P B, Fruchtman S M, Berlin N I, Wasserman L R. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.  Semin Hematol. 1986;  23 132-143
• 5 Fruchtman S M, Mack K, Kaplan M E et al.. From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera.  Semin Hematol. 1997;  34 17-23
• 6 Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment.  Semin Hematol. 1997;  34 29-39
• 7 Finazzi G, Barbui T. Treatment of essential thrombocythemia with special emphasis on leukemogenic risk.  Ann Hematol. 1999;  78 389-392
• 8 Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management.  Blood Rev. 2001;  15 121-131
• 9 Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequel of therapy, or a combination of both?.  Semin Hematol. 2004;  41 15-17
• 10 Berk P D, Wassermann L R, Fruchtman S M, Goldberg J T. Treatment of polycythaemia vera, a summary of clinical trends conducted by the polycythaemia vera sub-group. In: Wasserman LP, Berk PD Polycythaemia Vera and the Myeloproliferative Disorders. Philadelphia; WB Saunders 1995: 166-194
• 11 European Organisation for Research on Treatment of Cancer . Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomised trial. “Leukemia and Hematosarcoma” Cooperative Group, European Organisation for Research on Treatment of Cancer (EORTC).  Br J Cancer. 1981;  44 75-80
• 12 Baxter E J, Scott L M, Campbell P J et al.. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.  Lancet. 2005;  365 1054-1061
• 13 James C, Ugo V, Le Couedic J P et al.. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.  Nature. 2005;  434 1144-1148
• 14 Levine R L, Wadleigh M, Cools J et al.. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.  Cancer Cell. 2005;  7 387-397
• 15 Kralovics R, Passamonti F, Buser A S et al.. A gain-of-function mutation of JAK2 in myeloproliferative disorders.  N Engl J Med. 2005;  352 1779-1790
• 16 Campbell P J, Scott L M, Buck G et al.. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.  Lancet. 2005;  366 1945-1953
• 17 Passamonti F, Rumi E, Pietra D et al.. Relation between JAK2 (V617F) mutation status, granulocyte activation and constitutive mobilization of CD34-positive cells into peripheral blood in myeloproliferative disorders.  Blood. 2006;  107 3676-3682
• 18 Jones A V, Silver R T, Waghorn K et al.. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.  Blood. 2005;  107 3339-3341
• 19 Cortelazzo S, Finazzi G, Ruggeri M et al.. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.  N Engl J Med. 1995;  332 1132-1136
• 20 Monto R W, Tenpas A, Battle J F, Rohn R J, Louis J, Louis N B. A-8103 in polycythemia.  JAMA. 1964;  190 833-836
• 21 Brusamolino E, Salvaneschi L, Canevari A, Bernasconi C. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia.  J Clin Oncol. 1984;  2 558-561
• 22 Passamonti F, Brusamolino E, Lazzarino M et al.. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.  Haematologica. 2000;  85 1011-1018
• 23 Najean Y, Rain J D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.  Blood. 1997;  90 3370-3377
• 24 Landolfi R, Marchioli R, Kutti J et al.. Efficacy and safety of low-dose aspirin in polycythemia vera.  N Engl J Med. 2004;  350 114-124
• 25 Finazzi G, Caruso V, Marchioli R et al.. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.  Blood. 2005;  105 2664-2670
• 26 Modan B, Lilienfeld A H. Polycythemia vera and leukemia. The role of radiation treatment. A study of 1222 patients.  Medicine (Baltimore). 1965;  44 305-344
• 27 Tubiana M, Flamant R, Attie E, Hayat M. A study of hematological complications occurring in patients with polycythemia vera treated with 32P (based on a series of 296 patients).  Blood. 1968;  32 536-548
• 28 Chievitz E, Thiede T. Complications and causes of death in polycythemia vera.  Acta Med Scand. 1962;  44 155-157
• 29 Kiladjian J J, Gardin C, Renoux M, Bruno F, Bernard J F. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.  Hematol J. 2003;  4 198-207
• 30 Sterkers Y, Preudhomme C, Lai J L et al.. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.  Blood. 1998;  91 616-622
• 31 Merlat A, Lai J L, Sterkers Y et al.. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases.  Leukemia. 1999;  13 250-257
• 32 Chomienne C, Rain J D, Briere J. French PV and ET Study Groups. Risk of leukemic transformation in PV and ET patients.  Pathol Biol (Paris). 2004;  52 289-293
• 33 Rozman C, Giralt M, Feliu E, Rubio D, Cortes M T. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders.  Cancer. 1991;  67 2658-2663
• 34 Passamonti F, Rumi E, Pungolino E et al.. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.  Am J Med. 2004;  117 755-761
• 35 Berk P D, Goldberg J D, Silverstein M N et al.. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.  N Engl J Med. 1981;  304 441-447
• 36 Spivak J. Polycythemia vera: myths, mechanisms, and management.  Blood. 2002;  100 4272-4290
• 37 Andersson P O, Ridell B, Wadenvik H, Kutti J. Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment.  Ann Hematol. 2000;  79 40-42
• 38 Hsiao H H, Ito Y, Sashida G, Ohyashiki J H, Ohyashiki K. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia.  Leuk Res. 2005;  29 1247-1252
• 39 Chievitz E, Thiede T. Complications and causes of death in polycythaemia vera.  Acta Med Scand. 1962;  172 513-523
• 40 Petti M C, Spadea A, Avvisati G et al.. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).  Leukemia. 1998;  12 869-874
• 41 Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?.  Semin Hematol. 2004;  41 15-17
• 42 Halsey C, Roberts I A. The role of hydroxyurea in sickle cell disease.  Br J Haematol. 2003;  120 177-186